Prise en charge Intégrée des maladies de l’adolescent
et de l’adulte (PCIMAA)
Avril 2007
WHO/HTM/VIH/2007.01
WHO/HTM/TB/2007.380
Interium guidance, 25 June 2021Timely and accurate diagnostic testing is an essential tool in preventing and controlling the spread of COVID-19. This document describes recommendations for national testing strategies and the use of PCR and rapid antigen tests in different transmission scenarios of t...he COVID-19 outbreak, including how testing might be rationalized in low resource settings. All testing should be followed by a strong public health response including isolating those who test positive and providing them care, contact tracing and quarantine of contacts.
more
Orientação provisória 17 de março de 2020
Esta orientação rápida destina-se a profissionais de saúde pública e de prevenção e controle de infecção (PCI), gestores e profissionais de saúde, ao abordar questões relacionadas ao atendimento domiciliar de pacientes com suspeita de infecç...ão pelo nCoV que apresentem sintomas leves e o tratamento de contatos assintomáticos.
more
Este documento dá orientações sobre o uso de máscaras na comunidade durante a assistência domiciliar e em serviços de saúde em regiões que têm relatado casos de COVID-19. É dirigido a indivíduos na comunidade, profissionais de saúde pública e de prevenção e controle de infecção (PCI...), administradores da saúde, profissionais de saúde e trabalhadores da saúde comunitária. O documento será revisado à medida que mais dados se tornarem disponíveis.
more
18 Janaury 2021
EU/EEA Member States and the UK have increased their laboratory capacity tremendously over the past 11 months as the majority of the Member States reported sufficient testing capacity until March 2021.
Many countries are adding rapid antigen detection tests (RADT) to their ...testing strategies in order to reduce pressure on RT-PCR testing.
Some Member States have already included RADT in their case definition.
The main bottlenecks, such as shortages of laboratory consumables and human resources, as well as sample storing facilities, continue to exist and may affect the overall laboratory response to COVID-19.
more
Im Kapitel zu Diagnostik zum Nachweis von COVID-19 bekommen Sie ausführlich die verschiedenen Testmethoden erklärt, es können Videos zu PCR, RAchenabstrich, etc. aufgerufen werden
Limited coverage of laboratory services and long turnaround times from real-time reverse transcription-polymerase chain reaction (rRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been insufficient to meet the demands in many African countries in response... to the COVID-19 pandemic. Rapid antigen diagnostic tests (AgRDTs) are potentially useful as they can inform healthcare workers and individuals of their infection status at point-of-care testing
more
orientations provisoires, 25 juin 2021. Des tests de diagnostic rapides et précis sont un outil essentiel pour prévenir et contrôler la propagation du COVID-19. Ce document décrit les recommandations relatives aux stratégies nationales de dépistage et à l'utilisation de la PCR et des tests an...tigéniques rapides dans différents scénarios de transmission de l'épidémie de COVID-19, y compris la manière dont les tests pourraient être rationalisés dans les milieux à faibles ressources. Tous les tests doivent être suivis d'une réponse de santé publique forte, comprenant l'isolement des personnes dont le test est positif et la fourniture de soins, la recherche des contacts et la mise en quarantaine des contacts.
more
a dernière mise à jour a été effectuée dans le livret de la PCIME en 2014, mais depuis lors, des mises à jour importantes ont été effectuées sur la prise en charge du jeune nourrisson malade (MJN) âgé de moins de 2 mois. Cette mise à jour 2019 de la section sur le jeune enfant malade Pri...se en charge du jeune enfant malade âgé de moins de 2 mois : IMCI chart booklet. remplace le IMCI chart booklet de 2014. Les nouvelles mises à jour reflètent les récentes lignes directrices sur la prise en charge des infections bactériennes graves possibles (IPSP) chez les jeunes nourrissons lorsque l'orientation vers un spécialiste n'est pas possible, publiées en 2015. Elles comprennent l'évaluation, la classification et l'orientation de la SYI avec PSBI ; et le traitement ambulatoire de la SYI avec infection locale ou respiration rapide (pneumonie) chez les nourrissons âgés de 7 à 59 jours. Les autres mises à jour comprennent : une nouvelle section sur la manière de réévaluer, de classer et de traiter la SYI avec PSBI lorsque l'orientation n'est pas possible dans les établissements de santé ambulatoires par des agents de santé formés à la PCIME ; des changements dans l'évaluation et la prise en charge des jeunes nourrissons pour l'infection par le VIH ; et l'identification des nourrissons de moins de 7 jours de qui ont besoin de soins kangourou.
more
Protecting Patients, Supporting Practitioners in Tandem.
HRI Global is an independent health consultancy which specialises in Whole Health System Strengthening in the public and private sector by implementing the 12-Pillar Clinical Governance Programme (12-PCGP) in primary, secondary and tertiary h...ealth facilities/institutions; by working with the management and staff of the institutions and with local and national government. The programme protects patients and supports practitioners in tandem, enabling the facilities to become clinically governed to deliver quality and patient-centered care.
HRI Global is the founder and lead implementer of the 12-Pillar Clinical Governance Programme, which was designed and piloted in Cross River State, Nigeria, in 2004. HRI Global’s home-grown version of Clinical Governance is suitable for low and middle income countries (LMICs) in both government and privately-owned health facilities.
more
Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi...ng real-time or conventional polymerase chain reaction (PCR), for detection of unique sequences of viral DNA. PCR can be used alone, or in combination with sequencing. The recommended specimen type for laboratory confirmation of monkeypox is skin lesion material, including swabs of lesion surface and/or exudate, roofs from more than one lesion, or lesion crusts.
more
By end of March 2022:
42 COVID-19 detection laboratories were assessed in the 1st Quarter 2022.
23 (55%) Labs are reported fully functional, while 19 (45%) requires assistance to fully operate (i.e., medical supplies, equipment, maintenance, and staffing).
34 (89%) labs have RT-...PCR machines, while 4 (11%) doesn’t have.
Most laboratories operate 1 shift of 8 hours 13 (34%), followed by 2 shifts of 16 hours 11 (29%).
Over 1000 testing capacity per day is reported in Tripoli Biotechnical Centre Lab (5,000), Azzawya NCDC Lab (2,500), Tripoli NCDC public health lab (1500), Misrata NCDC Lab (1,300), and Misrata Medical centre Lab (1,300).
The reported needs ranked per priority are equipment, consumables, and staff training; consequently.
more
The meeting was held from 26 to 27 March 2018 to review and discuss the following topics:
Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs).
The status of development of rapid diagnostic tests (RDTs) targeting the M...UL_3720 protein.
The role of PCR as a reference test, and hurdles in providing a confirmatory diagnosis and in establishing a quality assurance programme.
New molecular tools with potential for implementation at a level lower than in the national or regional reference laboratory, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA).
The need to harmonize and standardize methods for collection and preparation of specimens, so samples can be referred for diagnosis and stored for evaluation of new diagnostic tests in optimal conditions.
Barriers to accessing early diagnosis and treatment, including coordination at the programme level, and lack of adequate diagnostic tools.
Defining target product profiles (TPPs) to guide the development of new diagnostic tools that can be applied at different levels of the health system. Participants agreed that two TPPs would be developed to address the current gaps: (i) a rapid test for BU diagnosis at the primary health-care level; and (ii) a test for diagnosis of BU that can also assist in treatment monitoring and differential diagnosis at the district hospital or reference centre.
more
With some 134,073,166 people living in endemic communities at risk of infection, Nigeria is the most endemic country in Africa and requires preventive chemotherapy (PC) for a total of 26.3 million persons. The National Schistosomiasis Elimination Programme (NSCHEP), with the support of international... partners, has been implementing PC in Nigeria since 2009 and most recently will need to revise its current strategy (Additional file 1). For example, the new World Health Organization (WHO) guideline has six key recommendations that will dramatically change the implementation of schistosomiasis elimination in endemic countries [3]. However, its impact and programmatic implications will vary from country to country, hence the need for a country-specific analysis. This article discusses these recommendations with specific reference to the challenges and opportunities in Nigeria. We summarise the key pointers in Additional file 1: Box 1 against the six recommendations of the WHO 2022 guideline.
more
This report represents the WHO-supported NTDs program activities and key performances in 2023. It is categorized into three sections: The first section states on the disease targeted for eradication (Guinea worm disease); the second section is on the
Preventive Chemotherapy (PC)-NTDs (Trachoma, ...Schistosomiasis, Soil Transmitted Helminthiasis, Onchocerciasis and Lymphatic Filariasis) and the third section is focused on the case management NTDs (Leishmaniasis, Leprosy, Human African
Trypanosomiasis, Noma and other skin NTDs).
more
Follow-up care is crucial but challenging for disease management particularly in rural areas with limited healthcare resources and clinical capacity, yet few studies have been conducted from the perspective of rural primary care physicians (PCPs). We assessed the frequency of follow-up care delivere...d by rural PCPs for hypertension and type 2 diabetes – the two most common long-term conditions.
more
Diabetes is one of the leading causes of death globally. India is home to the second-largest population suffering from diabetes. This underscores the need to build capacity of primary care physicians (PCPs) for better disease management. This narrative review article aims to describe the emergence o...f diabetes education and capacity-building programs for PCPs and its current situation in India. The review highlighted that major emphasis on diabetes was given only when the WHO estimated that morbidity and mortality due to diabetes would increase to 35% in India. As a result, National Diabetes Control Program was launched in 1987. Yet, very little attention was paid to diabetology in under-graduation. In the last decade, few public and private institutions have developed diabetes related capacity-building programs for PCPs independently or in collaborations. These programs include 16 fellowships, 4 diplomas, 12 certificate programs, and 6 other diabetes training programs, which have their own pros and cons. As medical science is changing rapidly, PCPs need to upgrade their skills and knowledge regularly to manage NCDs such as diabetes more effectively and efficiently. This can be possible only if scientific, evidence-based, and quality-oriented capacity-building programs are provided to the healthcare workforce.
more
On 27 September 2024, the Rwanda Ministry of Health announced the confirmation of Marburg virus disease (MVD). Blood samples taken from people showing symptoms were tested by real-time reverse transcription polymerase chain reaction (RT-PCR) at the National Reference Laboratory of the Rwanda Biomedi...cal Center and were positive for Marburg virus. As of 29 September 2024, a total of 26 confirmed cases, including eight deaths have been reported. The cases are reported from seven of the 30 districts in the country. Among the confirmed cases, over 70% are healthcare workers from two health facilities in Kigali.
more
Marburg and Ebola are filoviruses that cause hemorrhage, multiple organ failure, and high mortality rates. Diagnosis is with enzyme-linked immunosorbent assay, polymerase chain reaction (PCR), or electron microscopy. Treatment is supportive. Strict isolation and quarantine measures are necessary to ...contain outbreaks.
more
Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries.
In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response.
As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa.
more